Liquidia Price Target Maintained With a $25.00/Share by Needham
Where Liquidia Stands With Analysts
Here's What Analysts Are Forecasting For Liquidia Corporation (NASDAQ:LQDA) After Its First-Quarter Results
Express News | HC Wainwright & Co. Reiterates Buy on Liquidia, Maintains $29 Price Target
Analysts Have Conflicting Sentiments on These Healthcare Companies: COMPASS Pathways (CMPS), Liquidia Technologies (LQDA) and Regulus (RGLS)
Liquidia Technologies: Legal Wins and Promising Clinical Data Bolster Buy Rating
UTHR Files Patent Infringement Complaint Against Liquidia
United Therapeutics Corporation Filed A Complaint On May 9, 2025, In The U.S. District Court For The Middle District Of North Carolina Against Liquidia Alleging Infringement Of U.S. Patent No. 11,357,782.
Liquidia: Litigation Filed Against Company Alleges Infringement of United Therapeutics' '782 Patent >LQDA
Express News | Liquidia Corp: New Litigation Does Not Impact FDA's Ability to Take Final Action on Nda for Yutrepia on Pdufa Goal Date of May 24
Express News | Liquidia: Litigation Seeks to Enjoin Liquidia From Commercializing Yutrepia if Approved by U.S. FDA
Express News | Liquidia: New Litigation Filed Against Co in U.S. Alleges Infringement of United Therapeutics '782 Patent
Liquidia Corporation Provides Update on Litigation Filed by United Therapeutics
Liquidia First Quarter 2025 Earnings: Misses Expectations
Scotiabank Maintains Liquidia(LQDA.US) With Buy Rating, Maintains Target Price $36
Raymond James Maintains Liquidia(LQDA.US) With Buy Rating, Raises Target Price to $29
LifeSci Capital Maintains Liquidia(LQDA.US) With Buy Rating, Maintains Target Price $35
Raymond James Maintains Strong Buy on Liquidia, Raises Price Target to $29
Liquidia Analyst Ratings
Wells Fargo Maintains Liquidia(LQDA.US) With Buy Rating, Maintains Target Price $20